Background: In the Netherlands, limited variability exists in the performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This study offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin.

Conclusion: Patients achieving pCR and younger age had better OS and DFS. Compliance with treatment was 60%, largely affected by financial constraints in a resource-limited setting which emphasizes the importance of multidisciplinary clinics and cautious patient selection.Legal entity responsible for the study: The authors.